Cytori Therapeutics' (CYTX) Treatment of Impaired Hand function Due to Systemic Sclerosis Receives FDA Orphan Drug Designation

November 11, 2016 8:23 AM EST

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Cytori Therapeutics' (NASDAQ: CYTX) treatment of impaired hand function due to systemic sclerosis received FDA orphan drug designation.

Generic Name: Autologous stromal vascular cell fraction from adipose tissue (central facitily processed)
Trade Name: Eccs-50
Date Designated: 11/09/2016
Orphan Designation: Treatment of impaired hand function due to systemic sclerosis
Orphan Designation Status: Designated
FDA Orphan Approval Status:Not FDA Approved for Orphan Indication
Marketing Approval Date: N/A
Approved Labeled Indication:
Exclusivity End Date: N/A
Cytori Therapuetics, Inc.
3020 Callan Road
San Diego, California 92121
USA

The sponsor address listed is the last reported by the sponsor to OOPD.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, FDA

Add Your Comment